Markets

How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet

22 September 2026, 14:46 BST · Nasdaq

Centene Corporation’s CNC balance sheet is becoming an increasingly important part of the investment story. Stronger cash flow is giving the company room to reduce debt while preserving financial flexibility. That matters as the insurer works through payment-timing swings and navigates a shifting healthcare environment.

Centene generated nearly $8 billion from operations in the first half, partly reflecting the timing of Medicaid pass-throughs and working capital movements. More than $3 billion of Medicaid pass-through payments is expected to be paid out in the third quarter. While this should weigh on near-term cash, these payments do not affect key operating metrics such as the Health Benefits Ratio, SG&A expense ratio, or Days Claims Payable.

The company is also using receivables to support its balance-sheet improvement. In March 2026, it monetized a $1 billion participating interest in 2025 Part D risk-sharing receivables, generating $970 million to partially redeem senior notes. This gives Centene another source of liquidity beyond operating cash flow.

The impact is already visible in leverage. CNC repurchased $1.3 billion of senior notes in the first half, pushing its debt-to-capital ratio down to 41.6% from 46.5% as of year-end. With $981 million remaining under its repurchase authorization and no borrowings under its revolving credit facility, the focus now shifts to how effectively Centene uses its cash generation to further improve the balance sheet while funding operations.

How Are Competitors Faring?

Some of CNC’s major competitors in the managed-care space are Molina Healthcare, Inc. MOH and Elevance Health, Inc. ELV.

Molina Healthcare is also focused on strengthening cash generation while managing medical-cost pressure across its businesses. MOH’s operating cash flow improved to $788 million in the first half of 2026 from an outflow of $112 million a year earlier, despite its MCR increasing to 92.2%.

Elevance Health is balancing Medicaid payment timing with continued medical-cost pressures. ELV generated $1.9 billion of operating cash flow in the second quarter and ended June with $2.1 billion of parent-company cash and investments, providing added flexibility to support its balance-sheet and capital needs.

Centene’s Price Performance, Valuation & Estimates

Shares of CNC have gained 58.2% in the year-to-date period compared with the industry’s growth of 16.5%.

From a valuation standpoint, Centene trades at a forward price-to-earnings ratio of 12.48, below the industry average of 15.25. CNC carries a Value Score of A.

The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $4.89 per share, implying 135.1% growth from the year-ago period’s level.

CNC stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.